Clinical trials: Hematological Patients
CD7-Positive Hematological Malignancies
Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies
This study is a single-arm, multicenter Investigator-Initiated Trial (IIT) clinical study. The primary objective is to evaluate the safety, pharmacokinetic characteristics, and preliminary efficacy of CAR-T cells in subjects with…
- Trial name
- NCT07345780
- Testing
- CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Donghua Zhang
Metastatic Cancer, Cancer Recurrence
Parental Support Intervention in an Advanced Oncological Context
This prospective, two-arm randomized trial compares a psycho-educational program to a psycho-educational and experiential program for parents with advanced cancer.
- Conditions
- Metastatic Cancer, Cancer Recurrence, Hematological Cancer, Parent-Child Relations
- Trial name
- NCT07341815
- Testing
- Psycho-Education, Psycho-Experiential
- Where
- Belgium
- Volunteers
- 120 people
- Sponsor
- Université Libre de Bruxelles
Hematological Disorders
Hematology Biobank: In Vitro Study of Blood Disorders
This is a biorepository of blood specimens from subjects with different Hematological disorders.
- Trial name
- NCT02442011
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Albert Einstein College of Medicine
Malignancy, Cancer
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
This is a prospective interventional study designed to investigate the effect of Immune Reconstitution clinic visits and pneumococcal vaccination (PCV-21) on infection risk, anti-infective prophylaxis adherence, and vaccine…
- Conditions
- Malignancy, Cancer, Hematological Malignancies, Lymphoma
- Trial name
- NCT07071909
- Testing
- Commercial CAR-T, Investigational CAR-T
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematological Malignancy (Leukemia- Lymphoma)
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19…
- Trial name
- NCT07131254
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Grit Biotechnology
Hematological Patients, Bleeding
Administration of Fibrinogen Concentrate for Refractory Bleeding
Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients with thrombocytopenia. Patients with bone marrow failure secondary to haematological malignancy and chemotherapy frequently receive…
- Conditions
- Hematological Patients, Bleeding, Platelet Refractoriness
- Trial name
- FORMAT (NCT05091684)
- Testing
- Fibrinogen Concentrate Human
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Relapsed/Refractory Hematological Malignancies
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in…
- Trial name
- NCT07294300
- Testing
- QLS2313
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hematological Diseases
Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
The cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-HSCT in Denmark.
- Trial name
- NCT06277479
- Where
- Denmark
- Volunteers
- 1,262 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hematological Malignancies
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
It is hypothesized that engraftment when administering cyclophosphamide post the stem cell infusion will increase, the incidence of graft versus host disease (GVHD) and day 100 mortality will decrease, and the use of…
- Trial name
- NCT01349101
- Testing
- Total Body Irradiation, Cyclophosphamide, Tacrolimus
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hematological Malignancy
Membrane Target Detection for Leukemia Treatment
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis.
- Trial name
- NCT04841447
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Missouri-Columbia
Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)
The purpose of this study is to confirm that invariant NKT lymphocytes (iNKT) reconstitution in recipient and in the graft content can predict the outcome of human allogeneic HSCT and to set up an algorithm for clinical practice…
- Trial name
- REG-Allo (NCT02194868)
- Testing
- Recipients, Donors
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumors, Hematological Malignancies
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
This is a Phase 1, open-label, nonrandomized study to determine the PK profiles of belinostat in patients with relapsed/refractory solid tumors or hematological malignancies who have heterozygous and homozygous UGT1A1*28…
- Trial name
- NCT02680795
- Testing
- Belinostat IV
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Acrotech Biopharma Inc.
Acute Leukemia, Immune Deficiency Disorder
Umbilical Cord Blood Transplantation From Unrelated Donors
This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated…
- Conditions
- Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder
- Trial name
- NCT03016806
- Testing
- Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Hematological Malignancies
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
This is a Phase 1, multicenter, open-label clinical study of HMPL-506 administered orally in the treatment of hematological malignancies.
- Trial name
- NCT06387082
- Testing
- HMPL-506
- Where
- 16 sites in China
- Volunteers
- 132 people
- Sponsor
- Hutchmed
Invasive Fungal Disease, Chronic Disseminated Candidiasis
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
- Conditions
- Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation
- Trial name
- CANHPARI (NCT01916057)
- Testing
- 18F-FDG PET Scan
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematological Malignancies
The Study of ICP-248 in Patients With Mature B-cell Malignancies
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study…
- Trial name
- NCT05728658
- Testing
- ICP-248, ICP-248+Orelabrutinib, ICP-248 +Rituximab
- Where
- 22 sites in China
- Volunteers
- 191 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation
The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT)…
- Conditions
- Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Nursing Interventions, Symptom Management
- Trial name
- NCT07145359
- Testing
- Virtual Reality Intervention
- Volunteers
- 30 people
- Sponsor
- Halic University
Hematological Malignancies
18F-Pentixafor PET in Hematologic Malignancies
The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.
- Trial name
- NCT07122674
- Testing
- 18F-Pentixafor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
CD20-positive Hematological Malignancies
Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies
The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.
- Trial name
- NCT07110194
- Testing
- TQB2825 Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Relapsed and Refractory Hematological Malignancies
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies.
- Trial name
- NCT04008524
- Testing
- CAR-T cells
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China